Latest Impairment News

Coventry Group reports a challenging FY25 with a statutory loss driven by ERP implementation costs and asset impairments, while setting ambitious EBITDA targets for FY26 under refreshed leadership.

Coventry Group Ltd reported a challenging FY25 with a 1.7% revenue decline and a 40.9% drop in underlying EBITDA, culminating in a $29.6 million net loss. The company is now targeting over $20 million EBITDA in FY26 through aggressive cost reductions and operational recalibration.

Senetas Corporation reported a substantial $27.8 million net profit for FY2025, driven by the strategic sale of its Votiro business. The company also announced plans for a capital return and a major share consolidation ahead of a promising growth outlook.

AVADA Group Limited reported a revenue decline and a $9.7 million impairment on its New Zealand operations in FY25, while completing Phase 1 of its business transformation including ERP implementation and operational consolidation.

Locality Planning Energy Holdings reports a 79% rise in group profit excluding impairment, signaling a pivotal transformation as it outlines ambitious FY2026 growth plans.

Locality Planning Energy Holdings reported a modest revenue increase for FY2025 despite a significant impairment charge, as it pivots toward a disciplined, customer-focused multi-utility model.

Linius Technologies reported a $5.31 million loss for FY25 as it shifts towards a sales-driven SaaS model, with new leadership and cost-cutting measures aiming to reshape its future.

Adisyn Ltd reported a sharp increase in losses for FY25, driven by a 40% revenue drop and a costly acquisition, while securing significant new equity funding.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.